눈에 묻으면 몇 분간 물로 조심해서 씻으시오. 가능하면 콘택트렌즈를 제거하시오. 계속 씻으시오.
P332+P313
피부 자극이 생기면 의학적인 조치· 조언을 구하시오.
P337+P313
눈에 대한 자극이 지속되면 의학적인 조치· 조언를 구하시오.
P370+P378
화재 시 불을 끄기 위해 (Section 5. 폭발, 화재시 대처방법의 적절한 소화제)을(를) 사용하시오.
NFPA 704
0
2
0
INS 365 C화학적 특성, 용도, 생산
개요
Diquafosol (INS-365) was approved in Japan in 2010 as a 3%
ophthalmic solution for treatment of dry eye disease. Clinical diagnosis of dry eye is difficult because the condition
presents a variety of symptoms. Treatment options include tear
supplements (lubricants), anti-inflammatory drugs (e.g., cyclosporine
eye drops or steroid eye drops), and tear retention devices. Diquafosol
is a unique agent for the treatment of dry eye in that it acts as a P2Y2
purinergic receptor agonist with the ability to activate this receptor on
the ocular surface and stimulate water, lipid, and mucin secretion. Diquafosol is metabolized by phosphodiesterases to UTP, UDP, UMP, and uridine. Diquafosol has been well tolerated in clinical trials, with side effects being local to the ocular surface.In addition,no serious ocular or systemic adverse drug reactions were found
during the clinical trials.
용도
Enhancement of mucosal hydration in the treatment of chronic dry eye (P2Y2 receptor antagonist).
Clinical Use
Diquafosol tetrasodium was approved in April 2010 as Diquas ® ophthalmic solution 3% for the
treatment of dry eye syndrome and launched in Japan by Santen Pharmaceuticals. Diquafosol
tetrasodium was originally discovered by Inspire Pharmaceuticals. In 2001, it was licensed to Santen
for co-development and commercialization in Asian countries, and co-developed in collaboration with
Allergan for the countries outside of Asia. In the U.S., diquafosol tetrasodium was submitted for a New Drug Application (NDA) as Prolacria ®(2% ophthalmic formulation) in June 2003. However, it is still
in Phase III clinical development for dry eye syndrome. Diquafosol tetrasodium, also known as INS-
365, is a P2Y2 receptor agonist, which activates P2Y2 receptor on the ocular surface, leading to
rehydration through activation of the fluid pump mechanism of the accessory lacrimal glands on the
conjunctival surface.